Accueil
Marchés
Graphique & Idées
Algo
Nouvelles
Store
Courtiers
Télécharger
Calendrier Economique
Signaux de trading
Terminal Web
Tapez
/
pour rechercher : @user, $symbol
Recherche
Se connecter
Créer un compte
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
GDTC
#4969
CytoMed Therapeutics Limited Ordinary Shares
1.0
8
+5.88%
Secteur:
Base:
Devise de Profit:
Range quotidien
Range Annuel
Changement quotidien
+5.88%
Changement Mensuel
+35.00%
Evolution sur 6 mois
-46.27%
Changement Annuel
-59.85%
Clôture Précédente
1.0
2
Open
1.0
8
Bid
Ask
Low
1.0
8
High
1.0
8
Volume
1
Marchés
Actions des Marchés US
Soins de Santé
GDTC
Open full chart
Financials
Overview
Relevé
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
TTM
Key stats
Total common shares outstanding
11.53 M
11.54 M
11.54 M
—
Valuation ratios
Enterprise value
—
46.17 M
35.85 M
—
Price to earnings ratio
—
—
—
—
Price to sales ratio
—
—
—
—
Price to cash flow ratio
—
—
—
—
Price to book ratio
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
-0.6
-0.33
-0.25
—
Return on equity %
-5.34
-0.37
-0.28
—
Return on invested capital %
—
—
—
—
Gross margin %
—
—
100
—
Operating margin %
—
—
-907.91
—
EBITDA margin %
—
—
—
—
Net margin %
—
—
-3 628.51
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
0.6
14.08
9.89
—
Inventory turnover
—
—
—
—
Asset turnover
0
0
0.01
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
—
—
—
—
Net current asset value per share
—
—
—
—
Tangible book value per share
—
—
—
—
Working capital per share
—
—
—
—
Book value per share
—
—
—
—
Nouvelles
CytoMed Therapeutics fait le point sur ses thérapies cellulaires et essais cliniques
L’action CytoMed bondit après l’annonce d’un partenariat d’essai clinique en Malaisie
CytoMed stock jumps after announcing clinical trial partnership in Malaysia
CytoMed Therapeutics enters clinical trial agreement with Malaysian hospital
CytoMed Therapeutics obtient un investissement de 500.000 dollars pour sa filiale
CytoMed Therapeutics secures $500,000 investment for subsidiary
CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript
CytoMed annonce des résultats précliniques prometteurs pour un traitement contre la leucémie
CytoMed reports promising preclinical results for leukemia treatment
CytoMed Therapeutics shareholders approve all proposals at annual meeting
CytoMed Therapeutics schedules annual shareholder meeting